Evonik offers asymmetric recovery potential as €500 million of savings and niche leadership contrast with cyclical exposure, European cost disadvantages, and temporary logistics-driven earnings support.
Overview
Evonik Industries AG is a global specialty chemicals company organized around Custom Solutions, Advanced Technologies, and Infrastructure. It competes in specialized niches rather than high-volume commodities, supplying additives, active cosmetic ingredients, drug-delivery lipids, PA12 polymers, silicas, hydrogen peroxide, and DL-methionine to diversified industrial, pharmaceutical, agricultural, and consumer customers. Its moat rests on co-development, technical qualification, proprietary processes, integrated production assets, and supply security. **Q2 2026 demonstrated a sharp earnings recovery:** revenue rose 11% year over year to €3,893 million, adjusted EBITDA increased 24% to €630 million, the margin expanded to 16.2%, adjusted net income rose 85% to €296 million, and H1 FCF reached €232 million versus negative €16 million. Management raised 2026 adjusted EBITDA guidance to €2.0–€2.2 billion, sales guidance to around €15 billion, and maintained approximately 40% FCF conversion with €750 million capex. At approximately 5.5x EV/EBITDA on midpoint guidance, valuation is below pure-play specialty peers at 8x–10x. Near-term catalysts are cost savings, margin durability, and further guidance delivery; key offsets are shipping normalization, Chinese competition, European energy costs, and cyclical demand.